公开(公告)号：WO2012165926A2

公开(公告)日：2012-12-06

申请号：PCT/KR2012004396

申请日：2012-06-04

Applicant: KOREA RES INST OF BIOSCIENCE ,  CHO EUN WIE ,  HEO CHANG GYU ,  KO JEONG HEON ,  WOO MI KYUNG ,  YOO HYANG SOOK ,  HWANG HAI MIN

Inventor： CHO EUN WIE ,  HEO CHANG GYU ,  KO JEONG HEON ,  WOO MI KYUNG ,  YOO HYANG SOOK ,  HWANG HAI MIN

IPC: C07K16/30 ,  C12N5/16 ,  G01N33/53 ,  G01N33/574

CPC classification number: G01N33/57438 ,  C07K16/40 ,  G01N33/564

Abstract: The present invention relates to a fragment comprising an autoantibody which specifically binds to ATIC or an antigen-binding site (i.e. paratope) of the autoantibody, a composition for diagnosing liver cancer containing an agent which measures the expression level of the fragment, a hybridoma cell line producing the autoantibody, a diagnostic kit for liver cancer containing the composition, a method for diagnosing liver using the composition, and a method for screening a liver cancer therapeutic agent using the autoantibody. Using the anti-ATIC specific autoantibody of the present invention as a marker for diagnosing liver cancer, the occurrence of liver cancer can be diagnosed using a non-invasive biological sample such as blood, plasma, serum, lymph tissue, and the like, with a sensitivity of about 87% and a specificity of about 88%, and as liver cancer can be easily diagnosed using an amino acid sequence identified in the present invention, the autoantibody is effective for developing a diagnostic kit for liver cancer.

Abstract translation: 本发明涉及包含特异性结合ATIC或自身抗体的抗原结合位点（即辅助位点）的自身抗体的片段，用于诊断含有测定片段表达水平的试剂的肝癌组合物，杂交瘤细胞 产生自身抗体的线，包含该组合物的肝癌诊断试剂盒，使用该组合物诊断肝脏的方法以及使用该自身抗体筛选肝癌治疗剂的方法。 使用本发明的抗ATIC特异性自身抗体作为诊断肝癌的标志物，可以使用非侵入性生物样品如血液，血浆，血清，淋巴组织等来诊断肝癌的发生， 约87％的敏感性和约88％的特异性，并且可以使用本发明中鉴定的氨基酸序列容易地诊断为肝癌，所述自身抗体对于开发用于肝癌的诊断试剂盒是有效的。

公开(公告)号：WO2011046309A3

公开(公告)日：2011-09-15

申请号：PCT/KR2010006727

申请日：2010-10-01

Applicant: KOREA RES INST OF BIOSCIENCE ,  CHO EUN-WIE ,  HEO CHANG-KYU ,  WOO MI-KYUNG ,  HWANG HAI MIN ,  YOO HYANG-SOOK ,  KO JEONG-HEUN

Inventor： CHO EUN-WIE ,  HEO CHANG-KYU ,  WOO MI-KYUNG ,  HWANG HAI MIN ,  YOO HYANG-SOOK ,  KO JEONG-HEUN

IPC: C07K16/40 ,  C07K7/06 ,  C12N5/18 ,  G01N33/563 ,  G01N33/574

CPC classification number: G01N33/57438 ,  C07K16/303 ,  C07K16/40 ,  G01N33/5088 ,  G01N33/564

Abstract: The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.

Abstract translation: 本发明涉及特异性识别FASN（脂肪酸合成酶）的表位序列的自身抗体，更具体地，涉及自身抗体或其抗原结合位点的片段，包括能够评估 自身抗体的表达水平，产生自身抗体的杂交瘤细胞系，包含该组合物的肝细胞癌的诊断试剂盒，使用该组合物检测肝细胞癌患者的自身抗体的方法，以及用于筛选肝细胞癌治疗剂的方法 管理候选材料进行肝细胞癌治疗以确认自身抗体表达水平的降低。

公开(公告)号：WO2009093872A3

公开(公告)日：2009-11-05

申请号：PCT/KR2009000375

申请日：2009-01-23

Applicant: KOREA RES INST OF BIOSCIENCE ,  SEOUL PHARMA CO LTD ,  IND ACADEMIC COOP ,  HAN GYOONHEE ,  YANG JEE SUN ,  NAM MIHEE ,  LEE CHUL HO ,  SONG DOONA ,  WON MISUN ,  CHUNG KYUNG-SOOK ,  KIM DONG-MYUNG ,  YOO HYANG-SOOK ,  KIM HWAN MOOK ,  PARK SONG-KYU ,  LEE KIHO ,  LEE CHANG WOO ,  KO WONJIN ,  RYOO BYUNG-HWAN ,  CHOI NAM-SONG ,  JEONG YONG-MI

Inventor： HAN GYOONHEE ,  YANG JEE SUN ,  NAM MIHEE ,  LEE CHUL HO ,  SONG DOONA ,  WON MISUN ,  CHUNG KYUNG-SOOK ,  KIM DONG-MYUNG ,  YOO HYANG-SOOK ,  KIM HWAN MOOK ,  PARK SONG-KYU ,  LEE KIHO ,  LEE CHANG WOO ,  KO WONJIN ,  RYOO BYUNG-HWAN ,  CHOI NAM-SONG ,  JEONG YONG-MI

IPC: C07C211/62

CPC classification number: C07C311/05 ,  C07C233/36 ,  C07C233/43 ,  C07C311/08

Abstract: The present invention relates to a novel diamine compound or pharmaceutically acceptable salts thereof, method for preparing same, and a pharmaceutical composition for treating cancers containing same. The compound of the present invention exhibits superior effects of suppressing growth of tumor cells, and therefore can be valuable in treating cancer disease.

Abstract translation: 本发明涉及新型二胺化合物或其药学上可接受的盐，其制备方法和用于治疗含有其的癌症的药物组合物。 本发明的化合物表现出抑制肿瘤细胞生长的优异效果，因此在治疗癌症方面是有价值的。

公开(公告)号：WO2011071232A1

公开(公告)日：2011-06-16

申请号：PCT/KR2010/006113

申请日：2010-09-08

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  YEOM, Young Il ,  SOHN, Bo Hwa ,  PARK, In Young ,  LEE, Jung Ju ,  JANG, Yejin ,  YANG, Suk-jin ,  PARK, Kyung Chan ,  YOO, Hyang-sook ,  CHOI, Jong Young

Inventor： YEOM, Young Il ,  SOHN, Bo Hwa ,  PARK, In Young ,  LEE, Jung Ju ,  JANG, Yejin ,  YANG, Suk-jin ,  PARK, Kyung Chan ,  YOO, Hyang-sook ,  CHOI, Jong Young

IPC: C12Q1/68 ,  C12N15/11

CPC classification number: C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/154

Abstract: The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32 nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32 nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32 nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

Abstract translation: 本发明涉及一种使用由TTP（Tristetraprolin）启动子中的特定单个CpG位点组成的表观遗传标记和通过调节其表观遗传学状态来治疗癌症的癌症诊断和预后的方法。 特别地，本发明涉及通过测定由SEQ ID NO：1表示的核酸序列的第32位的C的特异性甲基化来诊断和预测肝癌的方法。 ID。 没有。 41，以及通过调节癌症治疗癌症的方法。 本发明可以有效地用于诊断和/或治疗特征为TTP下调和甲基化的肝癌，即SEQ ID NO：1所示的核酸序列的第32个残基。 ID。 没有。 41.本发明可以进一步应用于以TTP下调和甲基化为特征的其他癌症或炎性疾病的诊断和治疗，C为SEQ ID NO：1所示核酸序列的第32位残基。 ID。 没有。 41。

公开(公告)号：WO2007132967A1

公开(公告)日：2007-11-22

申请号：PCT/KR2006/004561

申请日：2006-11-03

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  KO, Jeong-Heon ,  KIM, Yong-Sam ,  YOO, Hyang-Sook ,  YOO, Jong-Shin ,  OH, Se-Jeong ,  KIM, Cheorl-Ho ,  KIM, Nam-Soon

Inventor： KO, Jeong-Heon ,  KIM, Yong-Sam ,  YOO, Hyang-Sook ,  YOO, Jong-Shin ,  OH, Se-Jeong ,  KIM, Cheorl-Ho ,  KIM, Nam-Soon

IPC: G01N33/53

CPC classification number: G01N33/574 ,  G01N2333/4724 ,  G01N2400/02

Abstract: The present invention relates to an analyzing method of measuring the changes of glycosylation in various glycoproteins which participate in carcinogenesis and metastasis.

Abstract translation: 本发明涉及测定参与癌发生和转移的各种糖蛋白中糖基化变化的分析方法。

公开(公告)号：WO2011046309A2

公开(公告)日：2011-04-21

申请号：PCT/KR2010/006727

申请日：2010-10-01

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  CHO, Eun-Wie ,  HEO, Chang-Kyu ,  WOO, Mi-Kyung ,  HWANG, Hai Min ,  YOO, Hyang-Sook ,  KO, Jeong-Heun

Inventor： CHO, Eun-Wie ,  HEO, Chang-Kyu ,  WOO, Mi-Kyung ,  HWANG, Hai Min ,  YOO, Hyang-Sook ,  KO, Jeong-Heun

IPC: C07K16/40 ,  C07K7/06 ,  G01N33/574 ,  G01N33/563 ,  C12N5/18

CPC classification number: G01N33/57438 ,  C07K16/303 ,  C07K16/40 ,  G01N33/5088 ,  G01N33/564

Abstract: The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.

Abstract translation: 本发明涉及特异性识别FASN（脂肪酸合酶）表位序列的自身抗体，更具体地涉及自身抗体或包含其抗原结合位点的片段，用于肝细胞的诊断组合物 包含能够评估自身抗体表达水平的试剂的癌，产生自身抗体的杂交瘤细胞系，包含该组合物的用于肝细胞癌的诊断试剂盒，使用该组合物检测肝细胞癌患者自身抗体的方法，以及用于 通过施用用于肝细胞癌治疗的候选材料来筛选肝细胞癌的治疗剂以确认自身抗体的表达水平降低。

公开(公告)号：WO2009048196A1

公开(公告)日：2009-04-16

申请号：PCT/KR2007/006124

申请日：2007-11-30

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  KO, Jeong-Heon ,  KIM, Yong-Sam ,  YOO, Hyang-Sook ,  YOO, Jong-Shin ,  OH, Se-Jeong ,  KIM, Cheorl-Ho ,  SON, Ok-Lye

Inventor： KO, Jeong-Heon ,  KIM, Yong-Sam ,  YOO, Hyang-Sook ,  YOO, Jong-Shin ,  OH, Se-Jeong ,  KIM, Cheorl-Ho ,  SON, Ok-Lye

IPC: G01N33/68

CPC classification number: G01N33/54313 ,  G01N33/6848 ,  G01N2400/00

Abstract: The present invention relates to an analyzing method of measuring the changes of glycosylation in various glycoproteins which participate in carcinogenesis and metastasis.

Abstract translation: 本发明涉及测定参与癌发生和转移的各种糖蛋白中糖基化变化的分析方法。

公开(公告)号：WO2008127078A1

公开(公告)日：2008-10-23

申请号：PCT/KR2008/002178

申请日：2008-04-17

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  WON, Mi Sun ,  KIM, Hwan Mook ,  CHUNG, Kyung-Sook ,  KIM, Dong-Myung ,  PARK, Song-Kyu ,  HAN, Gyoonhee ,  CHOI, Shin-Jung ,  LEE, Chang Woo ,  YOO, Hyang-Sook ,  LEE, Seung Hee ,  JANG, Young-Joo ,  SONG, Kyung Bin

Inventor： WON, Mi Sun ,  KIM, Hwan Mook ,  CHUNG, Kyung-Sook ,  KIM, Dong-Myung ,  PARK, Song-Kyu ,  HAN, Gyoonhee ,  CHOI, Shin-Jung ,  LEE, Chang Woo ,  YOO, Hyang-Sook ,  LEE, Seung Hee ,  JANG, Young-Joo ,  SONG, Kyung Bin

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: Disclosed herein is an anticancer agent comprising 4- hexadecanoyl-1,1-dimethyl-piperazin-1-ium iodide. The piperazine derivative effectively inhibits the proliferation of various cancer cells (in vitro ), and statistically significantly reduces tumor size and tumor weight in nude mice xenografted with human gastric carcinoma NUGC-3 cells when administered intraperitoneally to the mice (in vivo ). Also, the piperazine derivative blocks Ras signaling by downregulating farnesyltransferase, thereby inhibiting cell proliferation, and activates RhoB to thus upregulate JNKl/ JNK2, which causes the dysregulation of signaling via the mitochondria and increase the phosphorylation of Bcl-2, involved in cell survival, thereby inducing apoptosis within cells. Since the piperazine derivative inhibits the growth of tumor cells and induces apoptosis, it is useful in the treatment of various types of cancer.

Abstract translation: 本文公开了包含4-十六烷酰基-1,1-二甲基 - 哌嗪-1-碘化物的抗癌剂。 哌嗪衍生物有效地抑制各种癌细胞的增殖（体外），并统计学上显着降低了人胃癌NUGC-3细胞异种移植的小鼠（体内）时的肿瘤大小和肿瘤重量。 此外，哌嗪衍生物通过下调法呢基转移酶阻断Ras信号传导，从而抑制细胞增殖，并激活RhoB，从而上调JNK1 / JNK2，其引起通过线粒体的信号传导调节并增加参与细胞存活的Bcl-2的磷酸化， 从而诱导细胞内的凋亡。 由于哌嗪衍生物抑制肿瘤细胞的生长并诱导细胞凋亡，因此可用于治疗各种类型的癌症。

公开(公告)号：WO2008018778A1

公开(公告)日：2008-02-14

申请号：PCT/KR2007/003861

申请日：2007-08-10

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  SEOUL PHARMA. CO., LTD. ,  HAN, Gyoon Hee ,  CHOI, Eun Hyun ,  YANG, Jee Sun ,  HONG, Sung Hee ,  KIM, Myung Sook ,  WON, Mi Sun ,  CHUNG, Kyung Sook ,  KIM, Dong Myung ,  YOO, Hyang Sook ,  KIM, Hwan Mook ,  PARK, Song Kyu ,  LEE, Ki Ho ,  LEE, Chang Woo ,  CHOI, Youn Woong ,  JEONG, Yong Mi ,  MIN, Byung Gu

Inventor： HAN, Gyoon Hee ,  CHOI, Eun Hyun ,  YANG, Jee Sun ,  HONG, Sung Hee ,  KIM, Myung Sook ,  WON, Mi Sun ,  CHUNG, Kyung Sook ,  KIM, Dong Myung ,  YOO, Hyang Sook ,  KIM, Hwan Mook ,  PARK, Song Kyu ,  LEE, Ki Ho ,  LEE, Chang Woo ,  CHOI, Youn Woong ,  JEONG, Yong Mi ,  MIN, Byung Gu

IPC: C07D295/185 ,  C07D241/04 ,  C07D243/08 ,  A61P35/00

CPC classification number: C07D295/185 ,  C07D243/08 ,  C07D295/26

Abstract: The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a phar¬ maceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.

Abstract translation: 本发明涉及含有氮原子的新型杂环化合物或其药学上可接受的盐，其制备方法和包含其的用于治疗癌症的药物组合物。 根据本发明的化合物诱导由于活性氧物质引起的DNA损伤以激活c-abl和p53，诱导RhoB产生细胞凋亡，并通过下调参与细胞存活的Bcl2诱导细胞死亡，其由失调信号通过 线粒体途径，从而抑制肿瘤细胞生长并诱导细胞凋亡。 因此，本发明的组合物可以用于治疗癌症。

公开(公告)号：WO2012112013A3

公开(公告)日：2012-12-06

申请号：PCT/KR2012001264

申请日：2012-02-20

Applicant: KOREA RES INST OF BIOSCIENCE ,  CHO EUN WIE ,  HEO CHANG GYU ,  KO JEONG HEON ,  WOO MI KYUNG ,  YOO HYANG SOOK ,  HWANG HAI MIN

Inventor： CHO EUN WIE ,  HEO CHANG GYU ,  KO JEONG HEON ,  WOO MI KYUNG ,  YOO HYANG SOOK ,  HWANG HAI MIN

IPC: C07K16/18 ,  C12N5/16 ,  G01N33/574

CPC classification number: G01N33/57415 ,  C07K16/18 ,  C07K16/3015 ,  C07K2317/32 ,  C07K2317/34 ,  G01N33/564 ,  G01N2333/4742

Abstract: The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody.

Abstract translation: 本发明涉及细胞角蛋白8/18复合物特异性自身抗体或包含其抗原结合位点（互补位）的片段，其在诊断乳腺癌中的用途，具有特异性结合表位的氨基酸序列的多肽 涉及一种诊断乳腺癌的组合物，该组合物包含能够测定自身抗体或包含其抗原结合位点的表达水平的试剂，产生该自身抗体的杂交瘤细胞系和诊断乳腺癌的试剂盒， 本发明的组合物。 此外，本发明涉及使用本发明的组合物检测细胞角蛋白8/18复合物特异性自身抗体或包含其抗原结合位点的片段的方法，以及用于诊断乳腺癌的方法 使用自身抗体筛选乳腺癌治疗剂。